Analytical Data
-
基因名
HLA-A*0301 KRAS G12V Complex
-
简介
HLA-A*0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 55-60 kDa.
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
NP_002107.3 (G25-T305)&P61769
-
表达区间
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
分子量
55-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*0301 KRAS G12V complex recombinant protein is pivotal due to the critical role of KRAS mutations in cancer, particularly in pancreatic, colorectal, and lung cancers. The KRAS G12V mutation is one of the most common oncogenic alterations, driving tumorigenesis and contributing to cancer progression. Understanding how this specific mutation interacts with the major histocompatibility complex (MHC) molecule HLA-A*0301 is essential for advancing immunotherapy strategies. HLA-A*0301 is known for its ability to present specific peptide fragments derived from proteins, including mutated oncogenes, to T cells, thereby eliciting an immune response. By characterizing the KRAS G12V peptide complexed with HLA-A*0301, researchers aim to uncover the mechanisms of immune recognition and response to cancer cells harboring this mutation. This research has the potential to inform the development of personalized cancer vaccines and adoptive T cell therapies, targeting tumors expressing KRAS G12V. Moreover, by elucidating the structural and functional aspects of the HLA-A*0301 KRAS G12V complex, scientists can enhance understanding of immune evasion tactics used by cancer cells, which is vital for improving existing therapeutic modalities and discovering new approaches for cancer treatment.
